NALIRIFOX improved overall survival and progression-free survival in patients with metastatic pancreatic ductal adenocarcinoma.
April 2, 2023
Robert L. Ferris, MD, PhD, reflects on the status of telehealth in oncology and patient care following the COVID-19 pandemic.
Emerging data demonstrate the potential of these drugs to optimize survival, preserve quality of life, and even spare patients a radical cystectomy.
Emerging treatments, particularly claudin 18.2, a potential new biomarker in the HER2-negative gastric and gastroesophageal junction cancer space, were highlights of the 2023 ASCO Gastrointestinal Cancers Symposium.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
